

Procter & Gamble - I.P. Division**IMPORTANT CONFIDENTIALITY NOTICE**

The documents accompanying this telecopy transmission contain confidential information belonging to the sender which is legally protected. The information is intended only for the use of the individual or entity named below. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or the taking of any action in reliance on the contents of this telecopied information is strictly prohibited. If you have received this telecopy in error, please immediately notify us by telephone (collect) to arrange for return of the telecopied document to us.

RECEIVED
CENTRAL FAX CENTER


**FACSIMILE TRANSMITTAL SHEET AND
CERTIFICATE OF TRANSMISSION UNDER 37 CFR 1.8**

APR 15 2005

TO: - United States Patent and Trademark Office

Fax No. 703-872-9306 Phone No.

I hereby certify that this correspondence is being facsimile transmitted to the United States Patent and Trademark Office on April 15, 2005, to the above-identified facsimile number.

**FROM:** Linda S. Jernigan (Typed or printed name of person signing Certificate)

Fax No. 513-622-3300 Phone No. 513-622-2811

Listed below are the item(s) being submitted with
this Certificate of Transmission:**

- 1) Supplemental IDS - 4 pgs. - orig. w/copy
- 2) PTOSBO8 - 1 pg. - orig. w/copy
- 3)
- 4)
- 5)

Number of Pages Including this Page: 11

Inventor(s): Cox et al.
S.N.: 10/730,346
Filed: December 8, 2003
Docket No.:P148

Comments:

**Note: Each paper must have its own certificate of transmission, OR this certificate must identify each submitted paper.

Certification of Mailing or Faxed Transmission
 I hereby certify that I have reasonable basis to expect that, on the date shown below, this correspondence is being transmitted in the manner indicated:
 I mailed or deposited with the United States Postal Service with certificate postage at first class postage as airmail addressed to: Attn: U.S. Patent and Trademark Office for Patents, P. O. Box 1600, Alexandria, VA 22313-1430
 I am transmitting this document by facsimile to the U.S. Patent and Trademark Office at its number (ID) 872-9300

Linda S. Jernigan
 Name _____
 Signature _____
 Linda S. Jernigan
 Date: April 15, 2004

RECEIVED
 CENTRAL FAX CENTER

APR 15 2005

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No. : 10/730,346
 Applicant(s) : Cox et al.
 Filed : December 8, 2003
 Title : Edible Compositions Which Are Adapted For Use By A Companion Animal
 TCA/U. : 1761
 Examiner :
 Conf. No. : 1778
 Docket No. : P148
 Customer No. : 27752

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Mail Stop

Commissioner for Patents
 P. O. Box 1450
 Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 C.F.R. §§ 1.56, 1.97 and 1.98, record is being made on the attached Form PTO/SB08 of documents which the Patent Office may wish to consider in connection with examination of the above-identified patent application. It is respectfully requested that the cited documents be carefully considered by the Examiner and made of record in this case. As provided in §1.97(g), no representation is made or intended that a thorough art search was made. As provided in 37 C.F.R. §1.97(h), this Information Disclosure Statement does not constitute an admission of any kind, and specifically is not an admission that the documents listed on attached form PTO/SB08 are, or are considered to be, material to the patentability of the above-identified patent application, as defined in 37 C.F.R. §1.56(b).

1. 37 C.F.R. §1.97(b)(1) - U.S. Direct (use when filing IDS with nonprovisional patent application, or with Request for Continued Examination (RCE); or within 3 months of filing a nonprovisional patent application)

This information disclosure statement, submitted under 37 C.F.R. §1.97(b)(1), is being filed with the patent application, with a Request for Continued Examination or

within three months of the filing date of a national application. Therefore, no fee is believed to be due.

2. 37 C.F.R. §1.97(b)(3) - (use when filing IDS more than 3 months after filing a nonprovisional patent application, but prior to receipt of first Office Action)

This information disclosure statement is being submitted under 37 C.F.R. §1.97(b)(3). An Office Action on the merits in the present application has not yet been received. Therefore, no fee is believed to be due. However, in the event that this paper is crossing in the mail with a first Office Action on the merits, authorization is hereby given to charge the required fee pursuant to 37 C.F.R. §1.97(c) and 37 C.F.R. §1.17(p) to Deposit Account No. 16-2480 in the name of The Procter & Gamble Company. A duplicate of this letter (or a fee transmittal form) is enclosed to facilitate charging of the fee, if necessary.

3. 37 C.F.R. §1.97(b)(4) - (use when filing IDS prior to receipt of first Office Action after the filing of a Request for Continued Examination (RCE) under §1.114)

This information disclosure statement is being submitted under 37 C.F.R. §1.97(b)(4). A first Office Action after filing a Request For Continued Examination (RCE) has not yet been received. Therefore, no fee is believed to be due. However, in the event that this paper is crossing in the mail with a first Office Action on the merits, authorization is hereby given to charge the required fee pursuant to 37 C.F.R. §1.97(c) and 37 C.F.R. §1.17(p) to Deposit Account No. 16-2480 in the name of The Procter & Gamble Company. A duplicate of this letter (or a fee transmittal form) is enclosed to facilitate charging of the fee, if necessary.

4. 37 C.F.R. §1.97(c) with fee payment - (use when filing IDS after receipt of first Office Action, and before receipt of Final Office Action, Notice of Allowance, or an action that otherwise closes prosecution)

This information disclosure statement is being submitted under 37 C.F.R. §1.97(c). A final action under 37 C.F.R. §1.113, a notice of allowance under 37 C.F.R. §1.311, or an action that otherwise closes prosecution in the application (e.g., *Ex parte Quayle*) has not been received as of the date of this submission. I hereby elect to pay the fee set forth in 37 C.F.R. §1.17(p). Please charge the fee set forth in 37 C.F.R. §1.17(p) to Deposit Account Number 16-2480 in the name of The Procter & Gamble Company. A duplicate copy of this letter (or a fee transmittal form) is enclosed to facilitate the charging of the fee.

5. Information to be Considered with Continued Prosecution Application (CPA) Filing (use when filing IDS with a Continued Prosecution Application (CPA) for Design Case). This information disclosure statement is being filed with a Continued Prosecution Application (CPA) filed under 37 C.F.R. 1.53(d).

ADDITIONAL ITEMS TO BE NOTED BY THE EXAMINER:

In accordance with 37 C.F.R. §1.98(a)(2), copies of only foreign patent documents and non-patent literature are enclosed.

OR

All of the cited references were previously cited by or submitted to the USPTO in prior application Case No. ____, U.S. Patent Application Serial No. ___, filed ___. Priority is claimed to said application under 35 U.S.C. §120. Accordingly, copies of previously submitted references are not provided with this Statement, pursuant to 37 C.F.R. §1.98(d). It is respectfully requested that the cited documents be carefully considered by the Examiner and made of record in this case.

OR

Copies of all said documents, except Cite Numbers _____, were submitted and considered in parent application U.S. Patent Application Serial No. _____, filed _____. Priority is claimed to said application under 35 U.S.C. §120. Accordingly, copies of previously submitted references are not provided with this Statement, pursuant to 37 C.F.R. §1.98(d). Copies of references not previously submitted are enclosed. It is respectfully requested that the cited documents be carefully considered by the Examiner and made of record in this case.


Pursuant to 37 C.F.R. §1.98(c), a concise explanation of the relevance of each cited reference that is not in the English language is provided.

It is respectfully requested that the Examiner consider and make of record the co-pending applications listed on the attached page.

Additional information attached is generated from the International Search Report.

Respectfully submitted,

THE PROCTER & GAMBLE COMPANY



Signature

Kelly L. McDow-Dunham

Typed or printed name

Registration No. 43,787

(S13) 622-0159

Date: April 15, 2005

Customer No. 27752

(IDS.doc) (Last Revised 4/11/2005)

Please type a plus sign (+) inside this box → [+]

U.S. Patent and Trademark Office; U. S. DEPARTMENT OF COMMERCE

COMPLETE IF KNOWN

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.	
Substitute for Form 1449A/PTO	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)	
RECEIVED CENTRAL FAX CENTER APR 15 2005	
SHEET 1 of 1	
COMPLETE IF KNOWN	
Application Number	10/730,346
Confirmation Number	1778
Filing Date	December 8, 2003
First Named Inventor	Cox et al.
Group Art Unit	1761 4161
Examiner Name	Lori Mattison
Attorney Docket Number	P148

U. S. PATENT DOCUMENTS

Examiner Initials*	Case No.	Document Number Number - Kind Code* (if known)	Publication Date MM-DD-YYYY	Name of Inventor or Applicant of Child Document	Pages, Columns, Lines Where Relevant Paragraphs or Relevant Figures Appear
/L.K.M./		US-5,300,289	04-05-1994	The Dow Chemical Co.	
		US-5,380,530	01-10-1995	WhiteHill Oral Technologies	
		US-5,904,928	05-18-1999	Cyr et al.	
		US-			

FOREIGN PATENT DOCUMENTS

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not
considered. If no initial, state reason for nonconformance in communication to applicant.

considered. Include copy of this form with your communication to applicants.
"Applicant's unique citation designation" refers to the unique identification number assigned by the U.S. Patent and Trademark Office (USPTO) to each application. See 37 CFR 1.14 of the Code of Federal Regulations (CFR) for more information.
For Japanese patent documents, the indication of the year of the original of the applicant must precede the serial number of the patent document.
"Kind of document" by the appropriate symbols as indicated on the document under WIPO Standard ST-16 if applicable.
"A portion of it is living." check box here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 37 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including time for reviewing, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments or suggestions concerning the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

PL48-Event-RTO-SR/IN (Revised for P&G use 11/5/2004)

Certification of Mailing or Facsimile Transmission

I hereby certify that I have reasonable basis to expect that, on the date indicated below, this correspondence will be transmitted or delivered by the means indicated below:

mailed or deposited with the United States Postal Service with sufficient postage affixed thereto and to be postage advanced in accordance with the Regulations for Persons, P. O. Box 1450, Alexandria, VA 22313-1450

transmitted by facsimile to the U.S. Patent and Trademark Office on the number (703) 872-7500

Date: APR 15 2005
 Signature: Linda S. Ferrugino
 Name: Linda S. Ferrugino (if applicable)
 Signer's Title: Chief

RECEIVED
CENTRAL FAX CENTER

APR 15 2005

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No. : 10/730,346
 Applicant(s) : Cox et al.
 Filed : December 8, 2003
 Title : Edible Compositions Which Are Adapted For Use By A Companion Animal
 TC/A.U. : 1761
 Examiner :
 Conf. No. : 1778
 Docket No. : P148
 Customer No. : 27752

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Mail Stop

Commissioner for Patents

P. O. Box 1450
 Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 C.F.R. §§ 1.56, 1.97 and 1.98, record is being made on the attached Form PTO/SB08 of documents which the Patent Office may wish to consider in connection with examination of the above-identified patent application. It is respectfully requested that the cited documents be carefully considered by the Examiner and made of record in this case. As provided in §1.97(g), no representation is made or intended that a thorough art search was made. As provided in 37 C.F.R. §1.97(h), this Information Disclosure Statement does not constitute an admission of any kind, and specifically is not an admission that the documents listed on attached form PTO/SB08 are, or are considered to be, material to the patentability of the above-identified patent application, as defined in 37 C.F.R. §1.56(b).

1. **37 C.F.R. §1.97(b)(1)** - U.S. Direct (use when filing IDS with nonprovisional patent application, or with Request for Continued Examination (RCE); or within 3 months of filing a nonprovisional patent application)

This information disclosure statement, submitted under 37 C.F.R. §1.97(b)(1), is being filed with the patent application, with a Request for Continued Examination or

within three months of the filing date of a national application. Therefore, no fee is believed to be due.

2. 37 C.F.R. §1.97(b)(3) - (use when filing IDS more than 3 months after filing a nonprovisional patent application, but prior to receipt of first Office Action)

This information disclosure statement is being submitted under 37 C.F.R. §1.97(b)(3). An Office Action on the merits in the present application has not yet been received. Therefore, no fee is believed to be due. However, in the event that this paper is crossing in the mail with a first Office Action on the merits, authorization is hereby given to charge the required fee pursuant to 37 C.F.R. §1.97(c) and 37 C.F.R. §1.17(p) to Deposit Account No. 16-2480 in the name of The Procter & Gamble Company. A duplicate of this letter (or a fee transmittal form) is enclosed to facilitate charging of the fee, if necessary.

3. 37 C.F.R. §1.97(b)(4) - (use when filing IDS prior to receipt of first Office Action after the filing of a Request for Continued Examination (RCE) under §1.114)

This information disclosure statement is being submitted under 37 C.F.R. §1.97(b)(4). A first Office Action after filing a Request For Continued Examination (RCE) has not yet been received. Therefore, no fee is believed to be due. However, in the event that this paper is crossing in the mail with a first Office Action on the merits, authorization is hereby given to charge the required fee pursuant to 37 C.F.R. §1.97(c) and 37 C.F.R. §1.17(p) to Deposit Account No. 16-2480 in the name of The Procter & Gamble Company. A duplicate of this letter (or a fee transmittal form) is enclosed to facilitate charging of the fee, if necessary.

4. 37 C.F.R. §1.97(c) with fee payment - (use when filing IDS after receipt of first Office Action, and before receipt of Final Office Action, Notice of Allowance, or an action that otherwise closes prosecution)

This information disclosure statement is being submitted under 37 C.F.R. §1.97(c). A final action under 37 C.F.R. §1.113, a notice of allowance under 37 C.F.R. §1.311, or an action that otherwise closes prosecution in the application (e.g., *Ex parte Quicyle*) has not been received as of the date of this submission. I hereby elect to pay the fee set forth in 37 C.F.R. §1.17(p). Please charge the fee set forth in 37 C.F.R. §1.17(p) to Deposit Account Number 16-2480 in the name of The Procter & Gamble Company. A duplicate copy of this letter (or a fee transmittal form) is enclosed to facilitate the charging of the fee.

5. Information to be Considered with Continued Prosecution Application (CPA) Filing (use when filing IDS with a Continued Prosecution Application (CPA) for Design Case). This information disclosure statement is being filed with a Continued Prosecution Application (CPA) filed under 37 C.F.R. 1.53(d).

ADDITIONAL ITEMS TO BE NOTED BY THE EXAMINER:

[] In accordance with 37 C.F.R. §1.98(a)(2), copies of only foreign patent documents and non-patent literature are enclosed.

OR

[] All of the cited references were previously cited by or submitted to the USPTO in prior application Case No. ____ U.S. Patent Application Serial No. ___, filed ___. Priority is claimed to said application under 35 U.S.C. §120. Accordingly, copies of previously submitted references are not provided with this Statement, pursuant to 37 C.F.R. §1.98(d). It is respectfully requested that the cited documents be carefully considered by the Examiner and made of record in this case.

OR

[] Copies of all said documents, except Cite Numbers _____, were submitted and considered in parent application U.S. Patent Application Serial No. _____, filed _____. Priority is claimed to said application under 35 U.S.C. §120. Accordingly, copies of previously submitted references are not provided with this Statement, pursuant to 37 C.F.R. §1.98(d). Copies of references not previously submitted are enclosed. It is respectfully requested that the cited documents be carefully considered by the Examiner and made of record in this case.


[] Pursuant to 37 C.F.R. §1.98(c), a concise explanation of the relevance of each cited reference that is not in the English language is provided.

[] It is respectfully requested that the Examiner consider and make of record the co-pending applications listed on the attached page.

[X] Additional information attached is generated from the International Search Report.

Respectfully submitted,

THE PROCTER & GAMBLE COMPANY



Signature

Kelly L. McDow-Dunham

Typed or printed name

Registration No. 43,787

(513) 622-0159

Date: April 15, 2005
Customer No. 27752
(IDS.doc) (Last Revised 4/11/2005)

_____ + sign (+) inside this box $\rightarrow [+]$

SUPPLEMENTAL PTO/SB08A (08-03)

¹Under the Privacy Act, no person is required to respond to a collection of information unless it contains a valid OMB control number.

Form 1418A (PTO)

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

SHEET 1 of 1

COMPLETE IF KNOWN	
Application Number	10/730,346
Confirmation Number	1778
Filing Date	December 8, 2003
First Named Inventor	Cox et al.
Group Art Unit	1761 4161
Examiner Name	/Lori Mattison/
Attorney Docket Number	P148

U. S. PATENT DOCUMENTS

U.S. PATENT DOCUMENTS					
EXAMINER INITIALS*	CITE NO.	DOCUMENT NUMBER Number - Kind Code* (if known)	PUBLICATION DATE MM-DD-YYYY	NAME OF PUBLISHER OR APPLICANT OF CITED DOCUMENT	PAGE, COLUMN, LINE WHERE RELEVANT PASSAGES OR RELEVANT FIGURES APPEAR
/L.K.M.		US-5,300,289	04-05-1994	The Dow Chemical Co.	
/L.K.M.		US-5,380,530	01-10-1995	WhiteHill Oral Technologies	
/L.K.M.		US-5,904,928	05-18-1999	Cyr et al.	
		US-			

FOREIGN PATENT DOCUMENTS

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and note reason on this form with next communication to applicant.

considered. Include copy of this form with each communication to the Patent Office.
"Applicant's unique citation designation number (not communication number) from the Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04." Enter Office that issued the document by the appropriate symbols as indicated on the document under WOPO Standard ST.16 if the document is a Japanese patent document. The indication of the year of the reign of the Emperor must precede the serial number of the patent document. "Kind of document by the appropriate symbols as indicated on the document under WOPO Standard ST.16 if the document is a Japanese patent document, mark here if English language. Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 37 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application forms to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PL48_Sucral_STC-5B08 (Revised for P&G use 11/5/2004)